|
Adverse events
|
Studies(t)
|
Act-D-based regimen (n = 687)
|
MTX-based regimen (n = 987)
|
|---|
|
Patients(n1/n2)
|
%
|
Patients(n1/n2)
|
%
|
|---|
|
Hematologic disorders
|
|
Anemia
|
2
|
46/129
|
35.7
|
37/127
|
29.1
|
|
Leucocytopenia
|
3
|
27/208
|
13.0
|
24/182
|
13.2
|
|
Neutropenia
|
5
|
31/259
|
12.0
|
26/264
|
9.8
|
|
Thrombocytopnia
|
5
|
18/248
|
7.3
|
9/221
|
4.1
|
|
Gastrointestinal disorders
|
|
Constipation
|
3
|
32/134
|
23.9
|
19/110
|
17.3
|
|
Diarrhea
|
5
|
29/308
|
9.4
|
35/348
|
10.1
|
|
Nausea
|
9
|
167/405
|
41.2
|
85/427
|
19.9
|
|
Vomiting
|
9
|
92/436
|
21.1
|
43/449
|
9.6
|
|
Others
|
|
Alopecia
|
7
|
69/232
|
29.7
|
19/207
|
9.2
|
|
Anorexia
|
3
|
13/130
|
10.0
|
9/138
|
6.5
|
|
Fatigue
|
3
|
84/134
|
62.7
|
60/110
|
54.5
|
|
Liver toxicity
|
5
|
11/223
|
4.9
|
28/223
|
12.6
|
- Act-D Actinomycin D, MTX Methotrexate, t The number of studies reporting the toxicity, n Total number of enrolled patients, n1 The number of patients with adverse events, n2 the total number of patients from studies reporting the toxicity
